Keywords: Novartis, Vectura, QVA149, Seebri Breezhaler, Ph III, Regulatory filings, Sales projections

Novartis set to file QVA149 filing in EU and Japan by end of year

Article | 31 August 2012

Print This

Swiss drug major Novartis (NOVN: VX) announced yesterday that the fifth QVA149 (indacaterol maleate/glycopyrronium bromide) Phase III study, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in